Development of Liposomal Drug Delivery Systems Encapsulating Chemotherapeutic Agents with Surface Modification for Targeted Delivery to Breast Cancer Cells: In-Vitro Cytotoxicity, Cellular Uptake, and Stability Studies

Aditi Sharma, Rohan Mehta, Dr. Sneha Kulkarni

Department of Pharmaceutics, Rungta Institute of Pharmaceutical Sciences, Kohka Kurud, Bhilai

Rungta Institute of Pharmaceutical Sciences and Research, Bhilai, Chhattisgarh

1. Abstract

Breast cancer continues to be a major contributor to cancer-related illness and death globally, highlighting the need for more effective and less harmful treatment methods. Traditional chemotherapy drugs often lack specificity for tumors, resulting in systemic toxicity, drug resistance, and a lower therapeutic index. Liposomal drug delivery systems have emerged as a promising nanotechnology-based solution to these challenges by encapsulating chemotherapy drugs within phospholipid bilayer vesicles, which improve drug solubility, pharmacokinetics, and targeted tumor delivery. Modifying the surface of liposomes with targeting ligands, polymers, antibodies, and peptides allows for active targeting of specific receptors that are overexpressed on breast cancer cells, thereby increasing cellular uptake and cytotoxic effectiveness while reducing unintended effects. This research article thoroughly examines the development of liposomal drug delivery systems that encapsulate chemotherapy drugs with surface modifications for targeted delivery to breast cancer cells. It focuses on formulation design, physicochemical characterization, ligand conjugation strategies, and evaluation through in-vitro cytotoxicity, cellular uptake, and stability studies. Various liposomal preparation methods, such as thin-film hydration, reverse-phase evaporation, and ethanol injection, are critically assessed regarding encapsulation efficiency and particle size control. Surface functionalization techniques, including PEGylation, antibody conjugation, folate targeting, and peptide modification, are discussed in detail, highlighting their mechanistic role in receptor-mediated endocytosis and tumor-specific drug accumulation. Results from representative in-vitro studies show that ligand-modified liposomes exhibit enhanced cytotoxicity and cellular uptake compared to free drugs and non-targeted liposomes in breast cancer cell lines like MCF-7, SKBR-3, and MDA-MB-231. Additionally, stability assessments reveal improved drug retention, extended circulation time, and reduced premature drug leakage with surface modification. These findings underscore the potential of functionalized liposomal drug delivery systems as advanced nanocarriers for targeted chemotherapy in breast cancer treatment. The article concludes by highlighting future directions, including multifunctional liposomes, stimuli-responsive release systems, and translational challenges in clinical application.

2. Keywords

Drug delivery using liposomes; Targeting breast cancer; Liposomes with surface modifications; Encapsulation of chemotherapeutics; Cytotoxicity tests in vitro; Uptake by cells; Studies on stability; Nanocarriers; Chemotherapy with targeting; Liposomes with PEGylation; Endocytosis mediated by receptors.